Raymond James Financial
LUCD icon

Raymond James Financial’s Lucid Diagnostics LUCD Stock Holding History

Raymond James Financial’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$618K Buy
577,381
+52,445
+10% +$56.5K ﹤0.01% 4357
2026
Q1 		$604K Buy
+524,936
New +$668K ﹤0.01% 4223
2025
Q3 		– Sell
-791
Closed -$910 – 5969
2025
Q2 		$910 Buy
+791
New +$1.02K ﹤0.01% 6583

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Raymond James Financial's LUCD Position: Q2 2026 in Review

Raymond James Financial increased its Lucid Diagnostics (LUCD) stake by 10% in Q2 2026, buying an estimated $56.5K and bringing the position to 577,381 shares worth $618K. The position accounts for ﹤0.01% of the portfolio, ranked #4357.

Raymond James Financial first reported a position in LUCD in Q2 2025 and has held it in 3 quarters since. 115 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Raymond James Financial held 577,381 shares of Lucid Diagnostics worth $618K as of Q2 2026.
  • Raymond James Financial bought 52,445 Lucid Diagnostics shares in Q2 2026, an estimated $56.5K.
  • Lucid Diagnostics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4357 holding.
  • Raymond James Financial first reported a position in Lucid Diagnostics in Q2 2025 and has held it in 3 quarters since.
  • 115 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.